The David H. Koch Institute Professor, Massachusetts Institute of Technology
Robert S. Langer is the David H. Koch Institute Professor (The highest honor that can be awarded to a faculty member at MIT). Dr. Langer has written over 1,350 articles. He also has over 1,100 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 300 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history (h-index 222).
He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has received over 220 major awards. He is one of 4 living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry, the 2014 Breakthrough Prize in Life Sciences and the 2014 Kyoto Prize. He is also the only engineer to receive the Gairdner Foundation International Award; 82 recipients of this award have subsequently received a Nobel Prize. In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering.
SVP and COO, WuXi AppTec
Dr. Steve Yang is Executive Vice President and Chief Operating Officer of WuXi AppTec. He is also WuXi’s Head of Research Service Division. WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device R&D capability and technology open access platform company with operations in China, US, and Europe.
Dr. Yang is a pharmaceutical industry leader recognized for building R&D capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai. Previously, Dr. Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer’s global R&D strategic management group based in the United States.
Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco. He started his undergraduate study in Fudan University, China and completed his BS Summa Cum Laude from Michigan Technological University. He co-founded the BayHelix Group, a non-profit global professional organization of Chinese life science business leaders, and served as the chairman of the board for two terms.
General Partner, Flagship Ventures
David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics (NASDAQ: EBIO), Seres Therapeutics (NASDAQ: MCRB), Axcella Health, LS9 (acquired by Renewable Energy Group) and Indigo. David has served as founding CEO of Joule, Axcella Health and Seres. He currently serves on the boards of Eleven, Axcella Health and Avedro. He was previously a Board member of CGI Pharmaceuticals (acquired by Gilead), Joule, Seres and Indigo.
Prior to Flagship, David received an MD from Harvard Medical School and a PhD from the MIT Biological Engineering Division, working in the laboratories of Professors Ram Sasisekharan and Bob Langer, completing the dual degree in just over 5 years.
MD, PhD, CEO, CStone Pharma
With 25 years of research experience in US, Canada and China, Frank is the expert in drug development and clinical trial. Before joining CStone Pharma, Frank built reginol R&D of SANOFI Asia Pacifc Region and served as the President. During the last 5 years, he oversaw 80 clinical trials in Asia Pacific, including a 21,000-patient global ‘megatrial' for Lovenox (enoxaparin), leading to a successful global registration.
Managing Director, General Catalyst Partners
Mr. Hemant Taneja has been with General Catalyst Partners for 13 years. His investment thesis is based on an overall view that 21st century businesses will thrive on Economies of Unscale, and there is an incredible opportunity to redesign most application workflows with first principles. His investments at General Catalyst include ClassDojo, Fractyl, Gridco Systems, Gusto, Highfive, Livongo, SnapChat, Stripe, ThoughtSpot, Color Genomics and TuneIn.
Mr. Hemant Taneja holds five degrees from MIT: Electrical Engineering & Computer Science (BS and MS), Operations Research (MS), Mathematics (BS), Biology & Biomedical Engineering (BS).
Associate Professor, Brigham and Women's Hospital
Dr. Jeff Karp is a world leader in drug delivery, stem cell therapeutics, and tissue adhesives. Dr. Jeff Karp is an Associate Professor at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 100 peer-reviewed papers, has given over 200 national and international invited lectures and has 70 issued or pending patents.
The Boston Business Journal recognized him as a Champion in Healthcare Innovation and he was recognized by MIT’s Technology Review Magazine’s TR35. His work has been selected as one of Popular Mechanic’s “Top 20 New Biotech Breakthroughs that Will Change Medicine.” In 2015 he received a Breakthrough Award from the Kenneth Rainin Foundation and was a commencement speaker at the University of Toronto. He was recently named to the Top 40 Under 40 business leaders by the Boston Business Journal.
Partner, Sequoia China
Kevin Chen is a Partner at Sequoia Capital , responsible for healthcare investment. Kevin has led investment in many leading healthcare companies in China such as BGI, Amcare, Betta Pharmaceuticals Inc, JIDA Pharmaceuticals Inc, Yuwell Medical, Zai Lab, Medtrum Medical, STP, Bai Yang Pharmaceuticals, Forerunner Medical, Guahao, etc. He also served as President of ShangPharma and took the company public at NYSE in 2010.
Mr. Chen holds a bachelor degree in chemistry from Nanjing University, master degree in Medicinal Chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.
Sequoia China: over $1.4 billion USD fund, covering healthcare and TMT sectors
Managing and Founding Partner, HighLight Capital
Prior to founding HighLight, Steven was general partner and Investment Committee Member at CDH, one of China‘s largest private equity firms. Before that, Steven was the Director of Healthcare at Avenue Capital, Analyst at Lehman Brothers in London and manager of M&A at Becton Dickinson Group. Steven's past notable healthcare deals include: Kang Hong Pharma, Poly, Angel Women and Children's Hospital, New Century Children's Hospital, Kang Ning, New Eyes (430140), Evercare, King-Yee, TriPath Imaging, Inc. (NASDAQ: TPTH).
Steven received his MBA from London Business School, Master of Bio-Chemistry and Ph.D. qualification from NYU, and bachelor’s degree from Chinese Science and Technology University.
Founding President, QIAGEN Asia Pacific; General Partner, Serica Capital
Dr. Shi has 25 years’ experience in life science commercial operations, business development and investment. He is currently focusing on investing in diagnostics and medical devices in China. For ten years he has led commercial operations at QIAGEN in Asia Pacific. Previously he was a founding member or held senior positions at Aura Partners, Bridge Pharmaceuticals, Genospectra, A. M. Pappas & Associates. He was also a faculty member at National University of Singapore, School of Medicine and a cancer research scientist at Merck & Co.
Victor is currently Deputy Secretary-general of Chinese In-Vitro Diagnostics Industry Association, and a member of the China Board and Executive Committee of the Advanced Medical Technology Association (AdvaMed). He also serves on the board of Bayhelix, a global association of Chinese life science business executives. He obtained Ph.D. and M.S. degrees from the University of Rochester, New York, and B.S. degree from the University of Science and Technology of China.
Chairman and Chief Executive Officer, Simcere
Mr. Ren is the Founder of Jiangsu Simcere Pharmaceutical Company Ltd. and serves as its Chairman and Chief Executive Officer. Mr. Ren served as department manager of Jiangsu Pharmaceutical Industries Co., Ltd. from 1992 to 1995. From 1982 to 1992, he was the vice general manager of Qidong Gaitianli Medicines Co., Ltd. He serves as the Chairman of New Good Management Limited. Mr. Ren serves as a guest professor at the Nanjing University of Traditional Chinese Medicine and an adjunct professor of Northwest University in China. Mr. Ren graduated from the Nanjing University of Traditional Chinese Medicine in 1982 majoring in Chinese Medicine, and received a Master's degree in Economics from University of Macquarie in Australia in 2003.
Simcere Pharmaceutical Group ("Simcere" or the "Company") (SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. The company is planning to raise as much as $1 billion in a Hong Kong IPO in the coming months.
The company actively collaborates with domestic and international companies and research institutes to develop innovative drugs including biologics. We have successful formed partnerships with international companies including BMS, OSI (now Astellas), Epitomics (now Appexigen), GSK and Merck.
DongLiang Ge, President, BioScikin Co., Ltd.
Dr. Dongliang Ge is President of BioSciKin Co., Ltd., a China-based biotechnology company focusing on precision medicine diagnostics, drug innovation, incubating, investing and licensing. BioSciKin is a sister company of Simcere Pharmaceutical Group. Dr. Dongliang Ge is also appointed as member of U.S. NIH NHGRI Special Emphasis Panel, and Adjunct Assistant Professor at Duke University. Prior to BioSciKin, he was Director of Bioinformatics at Gilead Sciences, where he provided leadership to the corporate bioinformatics group and provided strategic input to the precision medicine infrastructure and process. Before Gilead, he was appointed as Assistant Professor of Medicine, Biostatistics and Bioinformatics at Duke University School of Medicine. He received his PhD of Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004. Dr. Ge was named by the Genome Technology magazine as one of the “rising stars” in 2009 and by Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015. He and his colleagues contributed to the clinical development of Sofosbuvir, a world-leading anti-HCV drug. His work in discovering the IL28B genetic variants associated with the hepatitis C patients’ response to clinical treatment, published in Nature in 2009, has received over 3000 citations to date. In total, his work has received over 15,000 citations.
Chairman of the Board and CEO, KingsMed Diagnostics
Mr. Liang Yaoming serves as the Chairman of the Board, Chief Executive Officer and President of Guangzhou KingMed Diagnostics.
Established in 1994 in Guangzhou, as a third-party medical laboratory group with the strongest comprehensive strength, largest size and fastest development speed in China, KingMed Diagnostics is mainly engaged in 4 major businesses including medical testing, clinical trials, food and hygiene testing, and scientific research service. It has provincial-level central laboratories in 21 cities in China (including Hong Kong) which can undertake more than 1,600 testing items as well as provide medical test outsourcing services for over 13,000 medical institutions in 30 provinces (municipalities, autonomous regions, special administrative region), covering 90% of the population area, strive to become the first supplier for clinical testing and pathology holistic solution in China. It was awarded several honors containing "China Top 10 Most Valuable Enterprise of Medical Health Industry", "21 Future Stars - China's Emerging Enterprise with The Fastest Growth", Forbes’s "Chinese Potential Enterprises", KingMed Diagnostics is one of the largest diagnostic testing companies in China with over 30% market share.
GM Strategy and Investment & Sr. Vice President, Medical Device, Fosun Pharma
Senior VP, Medical Device and GM of Strategy and Investment at Fosun Pharma, Mr. Richard Zhao holds an MBA degree from CEIBS and received executive education (CPD) from the Wharton School of University of Pennsylvania. He has about 20 years’ experience in M&A, Business Development and Sales & Marketing Management on both global and regional levels. Prior to joining Fosun Pharma, he held various executive positions at Bayer Healthcare and Philips Healthcare, driving international business growth and expansion. Richard has been one of early explorers in the 1990’s to introduce and help multinational companies enter and operate in China through Shanghai Free Trade Zone. In addition, he also has in-depth understanding of the value of startups and innovation through his personal entrepreneur experience.
Partner, Decheng Capital
Ted Driscoll brings 30 years of experience in health and imaging technology as an investor and entrepreneur. Ted is an expert on digital health and diagnostics, from big data and health technology to genomics and personalized medicine.
Ted has a successful track record of sourcing and leading the financing of promising digital healthcare startup companies, including Natera, GeneWeave BioSciences and AssureX Health. Ted currently represents CCV on the boards of Natera, AssureX, Numedii, Zipline Medical, GeneWeave, and Prime Genomics. He has previously served as a board member of Tibion (acquired by AlterG), GigaGen, and Fluxion Biosciences.
Prior to Claremont Creek, Ted founded five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, Broadcast and Videoconferencing technologies (now part of Google StreetView). He also served as CEO of Focus Surgery, spun off from Diasonics, and was previously Division President and CTO of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, and ablation technology businesses. Earlier, he led the Diasonics team that developed the first commercial MRI scanners. Previously, Ted was also Vice President of Engineering at Identix, then a world leader in digital fingerprint recognition (now used in the iPhone); and was Director of R&D at International Imaging Systems, an early pioneer in satellite remote sensing.
Ted was an angel investor with Life Science Angels and a founding director of the Sand Hill Angels and Health Tech Capital. He also has served as an elected council member of his home town, Portola Valley, for twenty years and five terms as Mayor.
Ted holds a PhD from Stanford University in Digital Imaging, two Masters degrees from Harvard University in Computer Graphics and Remote Sensing and a Bachelor's degree from the University of Pennsylvania. Ted holds 50+ granted US and foreign patents in imaging-related fields.
Chairman, BayHelix, Managing Partner, Serica Capital
Partner, Asset Management Ventures
Skip Fleshman has been at Asset Management Ventures (“AMV”) since 2002 and is actively investing in companies that focus on digital health, mobile and data analytics.
Skip was an officer in the United States Air Force where he first served as a fighter pilot flying the F-16. He flew 37 combat missions during Operation Desert Storm and also served as the wing expert in electronic combat systems and programs. He then founded and served as COO of BGI which develops software for flight simulators and training solutions for the aviation industry.
Skip is an advisor to Stanford’s StartX, Rock Health and Boston Children’s Hospital, as well as sitting on the board of Hiller Aviation Museum. He enjoys outdoor activities, fine wine, flying and attending the World Cup (six in a row now).
He received a Bachelor of Science degree in Mechanical Engineering from the University of California at Davis. Skip was a Sloan Fellow and received an M.S. in Management from the Stanford University Graduate School of Business.
Managing Partner, Vivo Capital
Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (DRTX), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).
Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.
Founder and Managing Partner, CTIC Capital
Yanhong Lin is the Founder and Managing Partner at CTIC Capital.  CTIC Capital provides investment banking services to companies in the field of Healthcare, IT and Energy. Yanhong and her team have successfully raised funding for US medical device companies and high tech companies.
Yanhong has close ties to venture capital firms in both Silicon Valley and Boston. She has established herself as a trusted advisor to VCs and entrepreneurs. Her clients are portfolio companies of top US VCs like General Catalyst, Khosla Venture, Prospect Venture, NEA and Third Rock. Her Chinese clients include top public traded Chinese companies.
Yanhong Lin has over 20 years of work experiences with Fortune 100 companies in the high tech and energy industries (Sun Microsystems, HP/Agilent and Amoco (now BP).  Prior to founding CTIC Capital, she led the Corporate Financial Planning and Analysis team at Sun Microsystems (a $12 billion revenue company) with responsibilities of company’s forecast and P&L analysis. 
Yanhong is a committee member of MIT Club of Northern California Energy and Environment, which was awarded the 2016 MIT Great Dome Award (is the highest honor that the MIT Alumni Association bestows upon any of its organizations).  She is also an advisor to the Stanford Precourt Institute for Energy and successfully helped Chinese companies get engaged with Stanford.  Yanhong was also served as Chair of the VC Taskforce China SIG (Special Interest Group).
Yanhong was born in Shanghai and grew up in Nanjing.  She received BA from Western Illinois University in 1991 and her MBA from University of Illinois at Champaign-Urbana in 1993. She lives with her husband and two Children in Palo Alto, California.  She enjoys skiing, traveling and spinning/biking.
Managing Director, CITIC PE
Mr. Wang is Managing Director of CITIC PE, in charge of Pharmaceutical, Medtech, and Biotech investments. He has over 15 years of experience of working in top global investment banks and direct investment firms.
Prior to CITIC PE, Mr. Wang was Head of Asia Pacific Healthcare from Credit Suisse. Before joining CS, Mr. Wang was a Managing Director of UBS’s China Investment Banking department, having led a number of Chinese healthcare and consumer IPOs and other capital raising deals. Previously, Mr. Wang worked with the Asia healthcare group and China Investment Banking Department at Morgan Stanley. Before returning to China in 2007, he worked and lived in the US, working for 7 years in multinational investment banks and multi-strategy hedge funds.
Before his finance career, Mr. Wang was a specialist in new medicine development, working as a senior research associate in new medicine R&D department of Schering-Plough Corporation (now part of Merck), and published 7 papers in professional magazines. He holds three international patent rights.Mr. Wang holds a Ph.D. in medicinal chemistry from Johns Hopkins University, and an MBA from New York University. He is also a CFA.
Venture Partner, Qiming Ventures
Dr. Jing-Shan Hu joined Qiming Venture Partners as Venture Partner in March 2016 and as Partner of Qiming US Healthcare Fund. She brings extensive experience in partnering, licensing, business development, R&D and management from three pharmaceutical multinational companies & two US biotech companies.
Before Qiming, she was at Bayer Healthcare Pharmaceuticals as VP and Head of (External) Innovation Center China, responsible for building partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing & External Research at Merck&Co (MSD), heading early stage partnering/licensing efforts in Greater China for Worldwide Licensing & External Research on novel drug candidates and technologies. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics & VEGF-2 Project Leader. While working at biotech companies, she has been successful in partnering with various organizations, including biotech industry and academia such as Stanford University.
Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ.
President and CEO, NinePoint Medical
Dr. Christopher von Jako brings extensive leadership and experience in the global medical device market with a specific expertise in image guided technologies. He has spent almost 25 years focusing on the development and commercialization of image-guided techniques to improve patient experience and outcomes. During this time, he has presented on the field of image-guided surgery in over 250 hospitals and medical congresses in North and South America, Europe, Africa, Asia, and Australia.
Most recently before joining NinePoint Medical in November of 2014, Chris was the President and CEO of NeuroTherm, a global medical device company that develops, manufactures, and markets state-of-the-art image-guided solutions for pain management utilizing radiofrequency ablation techniques. He successfully executed the divesture of NeuroTherm with his team in August 2014 to St. Jude Medical. Prior to that, Chris was the President of ActiViews, a privately held medical device company, which developed and marketed minimally invasive image-guided tools for Interventional Radiology. ActiViews was divested to a Fortune 500 medical device company. Previously, he served as Vice President of Marketing for the NeuroScience division at Integra LifeSciences from 2006 to 2010. He joined Integra LifeSciences as part of his successful divestiture of the Radionics business unit from Covidien, where Chris was the General Manager from 2003 to 2006. Prior to this, he worked as a Group Director at Medtronic’s Navigation business unit after successfully assisting in the orchestration of a strategic collaboration with Odin Medical Technologies, where he was the General Manager and Executive Vice President.
Chris holds a PhD in Biomedical Sciences from the University of Pécs Medical School (Pécs, Hungary), a Master of Science degree in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology (Cambridge, Massachusetts, USA), and a double BS degree in Physics and Mathematics from Bates College (Lewiston, Maine, USA).
Partner, Third Rock Ventures
Neil Exter joined Third Rock Ventures in 2007 and has more than 20 years of business development and strategic experience facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotechnology companies. He plays an integral role in the formation, development and business strategy for portfolio companies. Neil has served in key leadership roles in our portfolio companies:
• Board member of Cibiem
• Board member of CytomX Therapeutics
• Board member of Element Science
• Board member of Pliant Therapeutics
• Board member and former interim CBO of REVOLUTION Medicines
• Board member of Rhythm Pharmaceuticals
• Board member of Motus Therapeutics
• Former interim CBO of bluebird bio
• Former interim COO of Constellation Pharmaceuticals
• Former interim CBO of Foundation Medicine
• Former board member of Lotus Tissue Repair (sold to Shire)
• Former board member of Seventh Sense BioSystems
Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, leading the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive and senior management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories. Neil holds an MBA as a Baker Scholar from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University. He is a member of the Research Committee of Children’s Hospital Boston, a member of the investment committee of the Innovation Research Fund and Innovation Advisory Board at Partners Healthcare and the treasure and a member of the board of directors of the New England Venture Capital Association. In addition, Neil serves as a member of the Advisory Council of the Electrical and Computer Engineering Department at Cornell University and the board of visitors of Columbia College.
In college and post-college, Neil competed in several air guitar contests. He played air drums and air guitar.
CEO, Color Genomics
Elad is a renowned entrepreneur, operating executive, and investor or advisor to private companies such as AirBnB, Gusto, Optimizely, Pinterest, Square, Stripe, Wish, Zenefits.
Before Color Genomics founded, He was the VP of Corporate Strategy at Twitter, as well as ran various product teams (Geo, Search). Joined Twitter via the acquisition of MixerLabs. He spent many years at Google, where he started the mobile team and was involved in all aspects of getting the team up and running.
Prior to Google, had product management and market seeding roles at a number of Silicon Valley companies. Also worked at McKinsey & Co. Received Ph.D. from MIT and have degrees in Mathematics and Biology from UCSD.
Managing Director, CL Investment Group
Dr. Jimmy Zhang is the managing director, cross-border investment at CL Investment Group and President and CEO of CL Life Sciences (Shenzhen) Ltd. CL makes investments in the fields of biotech, medical devices and diagnostics, digital health, wearables, and life sciences-related VR/AR and AI. When these companies, projects and entrepreneurs have needs to expand and localize into China, our broadly-experienced team will help them to land in China as a launch- pad by functioning, as needed, as interim CEO and senior executives, and helping them to build their own management teams at their desired pace. Our deal structures are flexible: equity investment, JV, licensing, technology transfer, manufacturing, marketing and sales, etc., as fit by the partner. Our locations are broad: Silicon Valley, NYC, Boston, Los Angeles; Shanghai, Beijing, Shenzhen, Guangzhou, Chengdu, Wuhan, Xiamen, Langfang, Yiwu, etc.
Jimmy was former Vice President, Transactions, Johnson & Johnson Innovation. He was responsible for transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, and also responsible for fund relationship and partnership in the region.
Before joining J&J, Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co., and a member of Merck Research Lab (China) Senior Leadership Team.
Also he was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Previously, he was a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).
Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. Jimmy is a founding member and former Chairman of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, judges to State Thousand Talents Program, Guangzhou Innovation Talents, Chengdu Jing Rong Hui Venture Road Show and CHIC Business Plan Competition, a faculty member of Venture Capital Institute (China) and a guest/adjunct professor at Tongji University, Shanghai. Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on business development and doing business between US and China. He is often quoted in both US and Chinese news media.
Managing Director, Converge Minds
Clarence has over 25 years of experiences in petrochemical industry across China, Asia and the US. Strong track record in strategy formulation and implementation, sales and marketing, safety and operation management, project investment, JV management and M&A.
Before joining Converge Minds, he was VP of BP’s Global Acetyls business in charge of Greater China. This includes a manufacturing operation of over $600 million in annual sales revenue and investment plan in excess of $500 million in the region.
Clarence’s other roles in BP include VP of Sales, Marketing, Supply and Logistics for BP’s Asia Aromatics business. The role led a multi-national and location team in Asia to perform raw material procurement, logistics operation, marketing analyses and product sales functions. Total transaction (buy and sell) amounted to close to $4 billion.
Clarence also served as President of BP Zhuhai (BPZ) PTA Plant, BOD member of CAPCO and Formosa BP Acetyls in Taiwan, BOD member of YARACO, Byaco and BP Zhuhai in China, and vice president of PT Ami in Indonesia.
Clarence holds MBA from The University of Hull and Bachelor of Science in Chemical Engineering from De La Salle University.
Ph.D, MBA Partner, Frontline BioVentures
Dr. Vincent Xiang is a Partner of Frontline BioVentures. He has over 20 years of experience in the life sciences industries in the U.S. and China. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group (600079.SH), which has $1.3B/year in revenue in 2015. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, scouting first in class assets. From 2004 to 2012, Dr. Xiang was Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Previously, he was Vice President of business development at Genyous, a US biotech start-up. He was also Director of venture investment at Acacia Research, Associate at BioAdvance (a healthcare Angel fund), and Irvington Fellow at Skirball Center and licensed his patented technology to Millennium Pharmaceutical for royalty payments. Dr. Xiang began his career at Sinopharm in China. Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.
Managing Director, Legend Capital
Mr. OUYANG Xiangyu Joined Legend Capital in 2004. Since 2010, he has built up the team and led the investments in healthcare sector in the firm.
Mr. Ouyang has been a practitioner in the venture capital industry for 11 years and in the IT industry for 16 years. He has rich experience in company strategies, corporate governance, business operation, and venture investing.
From 2004 to 2010, some of the IT investments led by Mr. Ouyang include Sling Media, Fortinet(NASDAQ:FTNT), Lakala, Digital China Jinxin, Zhuhai Seine Technology, Eben and Watchdata.
Since 2010, healthcare deals led by Mr.Ouyang include Wuhan Asia Heart Hospital, BONOVO, Reach Surgical, ET Healthcare, Access Medical, Beijing Berrygenomics, U-Topstar, Jenavalve, Kailian Meidcal, KangDa Medical, DL Biotech and POCTech.
Mr. Ouyang joined Legend Group in 1992. He served as the general manager of the computer division of Apple in 1993 and general manager of the laptop division of Toshiba in 1996. He was the general manager of the Business Development Department of Legend Group in 1998, and associate president of Lenovo and general manager of Server and Network Storage Division in 2000.
Mr. Ouyang graduated from Wuhan University in 1986 with a bachelor’s degree. In 1992, he received a master’s degree in Electronic Engineering from Tsinghua University, and in 2009, he received his EMBA degree from the Cheung Kong Graduate School of Business.
M.D., Ph.D., Chairman & CEO, Ascentage Pharma Group
Dr. Yang is well-known for his comprehensive experience in targeted anti-cancer drug research and translating the research ideas into clinical development stage products, as well as operations and management experience. He has more than 25 years of experience in pharmacology, cancer biology and new drug discovery and development.
Dr. Yang co-founded Ascentage Pharma Group in 2009, and is the President & CEO since then.
Dr. Yang has established a China-based R&D team with international standards with several targeted oncology therapeutic NCE compounds in phase I and phase II trials in US, Australia and China. His team has proven track record in IND filing in the US and in China. In 2010, one of the MDM2-p53 inhibitors entered into a global R&D collaboration with Sanofi Aventis for a total of US$398 million. Before Ascentage Pharma, Dr. Yang co-founded US Ascenta Therapeutics in 2003, where he was Senior VP of Research and preclinical development, and completed near US$100 million financing with six top-tier biotechnology venture capital investors in US.
From 1995 to 2005, before returning to China, Dr. Yang was associate professor of internal medicine and member of the Comprehensive Cancer Center at the University of Michigan; and associate professor in the department of oncology and a senior investigator of the Lombardi Cancer Center at the Georgetown University Medical Center. Dr. Yang is author/co-author of more than 100 papers, book chapters, patents and abstracts. Dr. Yang is the inventor of more than twenty international patents (issued/pending).
Dr. Yang received “Special Contribution Award” from the SFDA for his contribution on modernization of the NCE drug guidelines in China. Dr. Yang also serves as part-time professor and Ph.D. supervisor at the Sun Yat-sen University Cancer Center, and visiting professor at China Pharmaceutical University. Dr. Yang obtained his M.D. in 1983 and Master degree in oncology in 1986, both from Sun Yat-sen University of Medical Sciences (SUMS). He received his Ph.D. in Genetics from Michigan State University in 1992. Dr. Yang served as president of the Chinese Biopharmaceutical Association (CBA) from 2003-2004.
Head and Managing Director, CEL Healthcare Fund
Mr. Bin Sun is currently Head and Managing Director of CEL Healthcare Fund, a private equity affiliate of China Everbright Limited. Previously he had worked at CICC Private Equity and AllianceBernstein Venture Fund. He had also been a research analyst with the AllianceBernstein’s global growth equity research team.  Prior to AllianceBernstein, he had worked in the corporate development group with Biogen Idec and as a researcher at Amgen.  He has played leading roles in private equity and strategic investment transactions totaling over USD 400 million transaction value. 
Mr. Sun holds a Master of Business Administration from New York University’s Stern School of Business and an M.S. in Pharmaceutics and Chemistry from the University of Michigan and the University of Kentucky.  He received his B.S. in Chemistry from Beijing University.